[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Tanzi S, Tiseo M, Internullo E, Cacciani G, Capra R, Carbognani P, Rusca M, Rindi G, Ardizzoni A: Localized malignant pleural mesothelioma: report of two cases. J Thorac Oncol; 2009 Aug;4(8):1038-40
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized malignant pleural mesothelioma: report of two cases.
  • Localized malignant pleural mesothelioma is very rare tumor disease.
  • There are sporadic reports in the literature showing that this entity has a different biologic behavior compared with diffuse pleural mesothelioma.
  • We report two cases of radically resected localized pleural malignant mesothelioma, with a previous history of asbestos exposure.
  • Both cases showed a microscopic and immunohistochemical findings of malignant mesothelioma, biphasic and sarcomatoid lympho-histiocitoid variant type, respectively, without evidence of diffuse pleural spread.
  • The first is very peculiar case of bilateral localized malignant pleural mesothelioma with complete response to chemotherapy and localized late recurrence, radically resected and treated with adjuvant radiotherapy.
  • The second case revealed as a solitary localized mass, underwent a complete en bloc resection and adjuvant radiotherapy.
  • Both cases demonstrate that the localized malignant mesothelioma should be distinguished from diffuse form and that complete resection is associated with good prognosis.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633479.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. De Pas T, Toffalorio F, Colombo P, Trifirò G, Pelosi G, Vigna PD, Manzotti M, Agostini M, de Braud F: Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac Oncol; 2008 Aug;3(8):938-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
  • Malignant solitary fibrous tumor (MSFT) of the pleura is a rare neoplasm, with unpredictable biologic behavior and a low sensitivity to chemotherapy.
  • To the authors' knowledge, no other effective medical treatment is available for this disease.
  • We report the first evidence of the activity of imatinib in a symptomatic patient with a chemo- and radio-resistant advanced MSFT, who obtained a 21-months lasting major clinical benefit with a consistent reduction in tumor metabolism.
  • Immunostaining of tumor cells demonstrated the positivity for PDGFR-alpha and PDGFR-beta and the absence of c-KIT over-expression, in the absence of c-KIT and PDGRFR mutations; all the cells strongly and diffusely expressed the ligand PDGF A in the cytoplasm.
  • This profile suggests that the observed tumor response was mediated through the inhibition of the tyrosine kinase activity of PDGFR.
  • Treatment with imatinib should be considered for patients with recurrent or unresectable MSFTs with PDGFR expression.
  • [MeSH-major] Piperazines / therapeutic use. Pleural Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism. Solitary Fibrous Tumor, Pleural / drug therapy
  • [MeSH-minor] Adult. Benzamides. Female. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Pneumonectomy. Protein-Tyrosine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / metabolism. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670317.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


3. Yamada N, Okuse C, Nomoto M, Orita M, Katakura Y, Ishii T, Shinmyo T, Osada H, Maeda I, Yotsuyanagi H, Suzuki M, Itoh F: Obstructive jaundice caused by secondary pancreatic tumor from malignant solitary fibrous tumor of pleura: a case report. World J Gastroenterol; 2006 Aug 14;12(30):4922-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice caused by secondary pancreatic tumor from malignant solitary fibrous tumor of pleura: a case report.
  • A 77-year-old man on systemic chemotherapy against postoperative bilateral multiple lung metastases of malignant solitary fibrous tumor of the pleura suffered from pruritus and jaundice.
  • Abdominal computed tomography showed a tumor with peripheral enhancement in the pancreatic head, accompanied with the dilatation of intra- and extra-hepatic bile ducts.
  • He was diagnosed as having obstructive jaundice caused by a pancreatic head tumor.
  • The pancreatic head tumor was presumably diagnosed as the metastasis of malignant solitary fibrous tumor of the pleura, because the findings on the pancreatic head tumor on abdominal CT were similar to those on the primary lung lesion of malignant solitary fibrous tumor of the pleura.
  • The pancreatic tumor grew rapidly after the implantation of metallic stent in the inferior part of the common bile duct.
  • The patient died of lymphangitis carcinomatosa of the lungs.
  • Autopsy revealed a tumor that spread from the pancreatic head to the hepatic hilum.
  • Immunohistochemically the pancreatic head tumor cells were negative for staining of alpha-smooth muscle actin (alpha-SMA) or CD117, but positive for vimentin, CD34 and CD99.
  • These findings are consistent with those on malignant solitary fibrous tumor of the pleura.
  • We report the first case of obstructive jaundice caused by a secondary pancreatic tumor from malignant solitary fibrous tumor of the pleura.
  • [MeSH-major] Jaundice, Obstructive / etiology. Neoplasms, Fibrous Tissue / pathology. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / secondary. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Autopsy. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2001 Sep;51(9):686-90 [11696171.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):538-43 [15086281.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):25-30 [10458214.001]
  • [Cites] Clin Radiol. 1982 May 3;33(3):297-9 [7075134.001]
  • [Cites] Ann Intern Med. 1985 Apr;102(4):487-90 [2983594.001]
  • [Cites] Surg Gynecol Obstet. 1989 Apr;168(4):345-7 [2928909.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • (PMID = 16937484.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4087636
  •  go-up   go-down


Advertisement
4. Lanuti M, Rudginsky S, Force SD, Lambright ES, Siders WM, Chang MY, Amin KM, Kaiser LR, Scheule RK, Albelda SM: Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res; 2000 Jun 1;60(11):2955-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
  • Previous studies with a mycobacterial heat shock protein (hsp-65) have demonstrated some efficacy using cationic liposome-mediated gene transfer in murine i.p. sarcoma models.
  • To further analyze the efficacy of hsp-65 immunotherapy in clinically relevant models of localized cancer, immunocompetent mice bearing i.p. murine mesothelioma were treated with four i.p. doses of a cationic lipid complexed with plasmid DNA (pDNA) containing hsp65, LacZ, or a null plasmid.
  • We observed >90% long-term survival (median survival, 150 days versus approximately 25 days, treated versus saline control, respectively) in a syngeneic, i.p. murine mesothelioma model (AC29).
  • In a more aggressive i.p. model of mesothelioma (AB12), we observed >40% long-term survival in groups treated with lipid:pDNA complexes, again irrespective of the transgene.
  • To ask whether these antitumor effects had led to an adaptive immune response against the tumor cell, we rechallenged long-term survivors in both murine models s.c. with the parental tumor cell line.
  • Specific, long-lasting systemic immunity against the tumor was readily demonstrated in both models (AB12 and AC29).
  • Consistent with these results, splenocytes from long-term survivors specifically lysed the parental tumor cell lines.
  • Lipid:pDNA treatment of athymic, SCID, and SCID/Beige mice bearing a murine i.p. mesothelioma (AC29) resulted in only a slight survival advantage, but there were no long-term survivors.
  • Treatment of immunocompetent mice depleted of specific immune effector cells demonstrated roles for CD8+ and natural killer cells.
  • An initial tumor cell killing stimulated by cationic lipid:pDNA complexes appears to be translated into long-term, systemic immunity against the tumor cell.
  • These results are the first to demonstrate that adaptive immunity against a tumor cell can be induced by the administration of lipid:pDNA complexes.
  • [MeSH-major] Bacterial Proteins. DNA, Bacterial / genetics. Genetic Vectors. Immunotherapy, Adoptive. Lipids / genetics. Mesothelioma / therapy
  • [MeSH-minor] Animals. CD8-Positive T-Lymphocytes / physiology. Chaperonin 60. Chaperonins / genetics. CpG Islands. Disease-Free Survival. Female. Gene Transfer Techniques. Killer Cells, Natural / physiology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred CBA. Mice, SCID. Plasmids. Spleen / drug effects. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10850443.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Chaperonin 60; 0 / DNA, Bacterial; 0 / Lipids; 0 / heat-shock protein 65, Mycobacterium; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


5. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • It is characterized by atypical solid growth of mesothelium with formation of atypical cavities surrounded by fibrous stroma.
  • Radical surgery can be used to treat localized mesothelioma.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


6. Veronesi G, Spaggiari L, Mazzarol G, De Pas M, Leo F, Solli P, Pastorino U: Huge malignant localized fibrous tumor of the pleura. J Cardiovasc Surg (Torino); 2000 Oct;41(5):781-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge malignant localized fibrous tumor of the pleura.
  • Localized fibrous tumor is an unfrequent mesenchymal neoplasm.
  • The malignant variant of the pleura is exceptional and differential diagnosis with the more frequent benign type or with other neoplasms such as soft tissue sarcoma and mesothelioma is rarely possible in a preoperative setting.
  • The best treatment of this disease is radical surgical resection.
  • No definitive data exist about the role of chemotherapy.
  • We report a case of a giant right intrathoracic mass whose preoperative diagnosis, from an open biopsy, was consistent with sarcoma and, in a second review, with fibrous tumor of the pleura without any indication about malignancy.
  • In consideration of the apparent local radicality we did not perform any adjuvant treatment.
  • Six months after the operation a wide local recurrence was evident and a systemic treatment with Ifosfamide and Adriamicina is still in progress.
  • Preoperative diagnosis of malignancy has an important role as a therapeutic strategy in management of fibrous tumours of the pleura.
  • When there is suspicion of a malignant form neoadjuvant chemotherapy can represent a further tool to control poorly differentiated and large tumors, and a wide surgical resection of the lesion must be performed.
  • [MeSH-major] Fibroma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pneumonectomy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149649.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


7. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, Yoo D: Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol; 2002 Feb;29(1):51-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience.
  • Peritoneal mesothelioma is a rare disease, but increasing in frequency.
  • The incidence is approximately one per 1,000,000 and about one fifth to one third of all mesotheliomas are peritoneal.
  • Because of its unusual nature, the disease has not been clearly defined either in terms of its natural history, diagnosis, or management.
  • Peritoneal mesothelioma patients generally present with two types of symptoms and signs; those with abdominal pain, usually localized and related to a dominant tumor mass with little or no ascites and those without abdominal pain, but with ascites and abdominal distention.
  • Prognosis as determined by clinical presentation, the completeness of cytoreduction, and gender (females survive longer than males) appears to be improved by the use of intraperitoneal chemotherapy.
  • Over the past decade, the management of these patients has evolved similarly to ovarian cancer treatment and now involves cytoreductive surgery, heated intraoperative intraperitoneal chemotherapy (HIIC) with cisplatin and doxorubicin, and early postoperative intraperitoneal paclitaxel.
  • These perioperative treatments are followed by adjuvant intraperitoneal paclitaxel and second-look cytoreduction.
  • Prolonged disease-free survival and reduced adverse symptoms with the current management strategy are documented by a high complete response rate as assessed by a negative second-look.
  • This multimodality treatment approach with cytoreductive surgery and intraperitoneal chemotherapy has resulted in a median survival of 50 to 60 months.
  • Peritoneal mesothelioma is an orphan disease that is treatable with expectations for "potential" cure in a small number of patients if diagnosed and treated early with definitive local/regional treatments.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 by W.B. Saunders Company.
  • (PMID = 11836669.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Cardillo G, Carbone L, Carleo F, Masala N, Graziano P, Bray A, Martelli M: Solitary fibrous tumors of the pleura: an analysis of 110 patients treated in a single institution. Ann Thorac Surg; 2009 Nov;88(5):1632-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the pleura: an analysis of 110 patients treated in a single institution.
  • BACKGROUND: Solitary (localized) fibrous tumors of the pleura (SFTP) are rare slow-growing neoplasms that generally have a favorable prognosis.
  • METHODS: The records of 110 patients (63 men; mean age 56.4 years; range, 17 to 79) surgically treated for SFTP from July 1990 to February 2008, were evaluated for demographics, operative procedure, histopathology, morbidity, mortality, postoperative chemotherapy or radiotherapy, and long-term follow-up.
  • The main surgical approach was video-assisted thoracoscopic surgery (69 procedures with a conversion rate of 14.5%); 40 patients underwent thoracotomy and 1 had sternotomy.
  • The visceral pleura was the site of origin in 95 tumors, the parietal pleura in 13, the mediastinal pleura in 2 cases.
  • Sixty-three tumors were pedunculated, 35 were sessile, and 12 were inverted fibroma.
  • Tumors were pathologically benign in 95 cases (86.4%), and malignant in 15 (13.6%).
  • The overall disease-free survival rate was 90.8% (95.7% in benign cases and 67.1% in malignant cases; p < 0.05).
  • Eight patients presented with recurrence of disease, 4 cases of which were malignant and 4 were benign.
  • CONCLUSIONS: Solitary fibrous tumor of the pleura is a rare disease that includes both benign and malignant variants.The outcome is mostly benign, with an overall 10-year survival rate of 97.5%.
  • Pathologically benign lesions show a better disease-free survival rate than malignant lesions (95.7% versus 67.1%; p < 0.05).
  • Surgery is the gold standard of treatment as neither radiotherapy nor chemotherapy proved to be effective.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19853123.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Tamura E, Kozaki M, Kunimoto M, Tokuyama S, Kawanami Y, Watanabe H, Hamada T, Morooka M, Mukae H: [A case of localized malignant pleural mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2010 Jul;48(7):511-5
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of localized malignant pleural mesothelioma].
  • A chest computed tomography (CT) scan revealed a 5-cm mass attached to the pleura involving the right upper lobe, and a nodule in the right middle lobe.
  • Transbronchial lung biopsy was performed twice, but no definitive diagnosis was achieved.
  • 18-fluorodeoxyglucose positron emission tomography showed abnormal uptake in the chest lesion.
  • Chemotherapy was initiated for advanced-stage lung cancer, but was not effective.
  • Histopathologic and immunohistochemical examinations after CT-guided needle biopsy revealed malignant mesothelioma.
  • The tumor cells were positive for calretinin and thrombomodulin, and negative for CEA, TTF-1, and SP-A.
  • There was local tumor invasion and metastasis in the lung and brain, without diffuse pleural spread.
  • This is a rare and important case of localized malignant mesothelioma pathologically confirmed by biopsy.
  • [MeSH-major] Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684215.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Jänne PA, Baldini EH: Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin; 2004 Nov;14(4):567-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure following surgical resection for malignant pleural mesothelioma.
  • The optimum therapeutic strategy for patients with localized malignant mesothelioma continues to evolve.
  • An encouraging 45% 5-year survival rate has been reported for patients with early-stage disease who undergo EPP and have the favorable features of epithelial histology and the absence of mediastinal lymph node involvement.
  • Most patients present with more advanced disease, however, and the optimum local and systemic treatment for these patients has not been defined.
  • No randomized trials evaluating the various surgical or adjuvant therapeutic approaches have been performed.
  • Evaluation of treatment efficacy based on observed patterns of failure may suffer from treatment selection biases.
  • Most studies also do not separate out the failure patterns based on the initial stage (clinical or pathologic) of the disease.
  • Consequently, it is difficult to discern the potential impact of a given adjuvant therapy.
  • Efforts to decrease the chance of local recurrence after P/D have included the use of intrapleural and intravenous chemotherapy, brachytherapy, and external beam radiation therapy.
  • None of these adjuvant treatment trials was randomized, and when compared with historical controls, none of the treatments used suggested a consistent outcome benefit.
  • Doses required to treat mesothelioma effectively are above the doses that would lead to damage to the lung parenchyma.
  • Cisplatin and mitomycin have been used as agents have modest activity against mesothelioma.
  • Alternative approaches for patients who undergo P/D, such as the use of escalating doses of heated intrapleural cisplatin (given with a renal protecting agent, sodium thiosulfate, which provides the opportunity to deliver higher doses of chemotherapy), are being pursued by Sugarbaker et al.
  • The availability of more active systemic chemotherapy agents or other intrapleural agents also may offer better therapeutic options for patients who undergo P/D.
  • Recently, Vogelzang et al presented the findings of a large randomized study that compared cisplatin/premetrexed to cisplatin and demonstrated an improvement in response rate (41% for cisplatin/pemetrexed versus 19% for cisplatin) and median survival (12.1 versus 9.3 months, respectively; P = 0.020).
  • Other chemotherapy regimens with encouraging activity in mesothelioma include the combination of cisplatin and gemcitabine, with response rates ranging from 16% to 48%.
  • From a review of available data, patients with mesothelioma who have undergone P/D (with or without intrapleural chemotherapy) who are evaluated at the Dana Farber Cancer Institute and Brigham and Women's Hospital are offered therapy with systemic chemotherapy alone.
  • After P/D, radiation is used only for palliative treatment.
  • Patients who have undergone P/D are also appropriate candidates to receive chemotherapy or other novel therapeutic strategies being evaluated in clinical trials.
  • This observation may represent a shift of the natural history of the disease.
  • Metastatic mesothelioma is often seen late in the course of the disease, but it may become the dominant source of disease after aggressive local surgical management.
  • Many studies define abdominal recurrence as a site of distant recurrence, although this may represent transdiaphragmatic extension of the pleural mesothelioma.
  • Advances in local therapy also may decrease the rate of abdominal recurrences.
  • The lowest rate of local recurrence (13%), with a 4% local-only recurrence rate, was seen in the study by Rusch et al, who used 54 Gy hemithorax radiation as adjuvant therapy.
  • Baldini et al reported a 50% local recurrence rate, with a 13% local-only rate, after trimodality therapy.
  • One possibility for the differences between these two reports is the lower dose of radiation (30.6 Gy) used in the latter study.
  • In the study by Rusch et al, distant failures predominate, and the patients are appropriate candidates for systemic chemotherapy, which could be administered either as neoadjuvant or adjuvant therapy.
  • Kestenholz et al currently are performing a phase II clinical trial of neoadjuvant cisplatin and gemcitabine administered for three cycles followed by EPP and adjuvant radiation therapy.
  • A similar approach also is being pursued in an ongoing clinical trial using neoadjuvant cisplatin/pemetrexed for four cycles before EPP followed by 54 Gy of adjuvant hemithorax radiation.
  • Alternatively, patients who have undergone EPP could be treated with adjuvant chemotherapy in addition to adjuvant radiation therapy.
  • Currently, patients evaluated at the Dana Farber Cancer Institute and Brigham and Women's Hospital who have undergone EPP are offered adjuvant chemotherapy followed by hemithorax radiation to 54 Gy in an effort to maximize local and distant control rates.
  • Further clinical studies are needed for all patients with mesothelioma to define the optimum surgery and duration and types of adjuvant therapy.
  • The appropriate multimodality approaches most likely will differ based on disease stage, histology, and patient performance status. intrapleural chemotheraphy treatments.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Treatment Failure

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15559064.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


11. Sethna K, Sugarbaker PH: Localized visceral invasion of peritoneal mesothelioma causing intestinal obstruction: a new clinical presentation. Hepatogastroenterology; 2005 Jul-Aug;52(64):1087-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized visceral invasion of peritoneal mesothelioma causing intestinal obstruction: a new clinical presentation.
  • Peritoneal mesothelioma is a surface malignancy involving the serous surfaces of the abdominal cavity.
  • In the case presented here, the disease presented itself in a manner that has not been previously described.
  • The tumor involved the full thickness of the bowel besides the familiar surface spread which is characteristic of the disease.
  • Intestinal obstruction is a rare or late presentation of mesothelioma.
  • It was the presenting symptom in the present case due to the full thickness infiltration of the small bowel by the tumor.
  • The offending segment was resected and the ascites was treated with intraperitoneal chemotherapy.
  • Though the patient at present has progression of disease he enjoys a reasonable quality of life after palliation of the ascites and obstruction.
  • [MeSH-major] Intestinal Obstruction / etiology. Mesothelioma / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001635.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Vigneswaran WT, Stefanacci PR: Pericardial mesothelioma. Curr Treat Options Oncol; 2000 Oct;1(4):299-302
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial mesothelioma.
  • Primary pericardial mesothelioma is a rare but lethal disease.
  • Surgical resection remains the main treatment modality.
  • When the disease is localized and completely resected, long-term survival can result.
  • Most often the tumor invades the myocardium or the great vessels and therefore is at best palliative in relieving pericardial tamponade or constriction.
  • Addition of chemotherapy or radiation has been disappointing.
  • Newer therapeutic approaches for malignant pleural mesothelioma are likely to influence the treatment of pericardial mesothelioma in the future.
  • [MeSH-major] Heart Neoplasms / therapy. Mesothelioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Pericardium / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1995 Jul;222(1):78-86 [7618973.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1559-65 [8336195.001]
  • [Cites] J Nucl Med. 1987 Jul;28(7):1210-2 [3474368.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):802-3 [1514518.001]
  • [Cites] Ann Surg Oncol. 1995 May;2(3):214-20 [7641017.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Am Rev Respir Dis. 1978 Aug;118(2):419-24 [697191.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):660-1 [7993848.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2577-82 [10375105.001]
  • [Cites] Environ Res. 1980 Dec;23(2):270-81 [7472312.001]
  • [Cites] Tex Heart Inst J. 1994;21(2):170-4 [8061543.001]
  • [Cites] Chest. 1982 Apr;81(4):520-3 [7067523.001]
  • [Cites] Postgrad Med J. 1992 Feb;68(796):137-9 [1570257.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Cancer. 1970 Oct;26(4):914-9 [5506612.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1987;21(3):273-5 [3438724.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(6):420-6 [1934246.001]
  • (PMID = 12057155.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


13. Eren NT, Akar AR: Primary pericardial mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):369-73
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial mesothelioma.
  • Pericardial mesothelioma is a rare cancer for which treatment options are limited.
  • Operative intervention in pericardial mesothelioma is primarily for effusion control, for cytoreduction before multimodal therapy, or to deliver and monitor innovative intrapericardial therapies.
  • Early detection of the disease is the only hope for survival.
  • Failure of surgical techniques is usually associated with mesothelioma with entrapped heart, a large solid tumor mass, and a long history of pericardial effusion.
  • If the tumor is localized, resection is the only hope for this rare, but lethal, entity.
  • No single treatment modality is efficient by itself.
  • The exact role of intracavitary chemotherapy or irradiation remains to be defined.
  • Preliminary clinical application of photodynamic therapy and attempts at inhibiting the effects of growth factors, such as vascular endothelial growth factor and platelet-derived growth factor, and vaccine treatments are being explored.
  • Adenoviral molecular chemotherapy recently completed phase I testing.
  • Clinical trials for pleural mesothelioma remain important as clinicians seek to improve the outcome for patients with pericardial mesothelioma.
  • In the future, combined therapeutic strategies involving radical surgery, radiotherapy, adjuvant chemotherapy, and immunomodulation may have a role in the treatment of pericardial mesotheliomas.
  • [MeSH-major] Heart Neoplasms / drug therapy. Heart Neoplasms / prevention & control. Heart Neoplasms / surgery. Mesothelioma / drug therapy. Mesothelioma / prevention & control. Mesothelioma / surgery. Pericardium / pathology
  • [MeSH-minor] Humans. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Surg (Torino). 2001 Jun;42(3):425-7 [11398045.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):321-36 [9205997.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):695-700 [6668488.001]
  • [Cites] Ann Thorac Surg. 1967 Feb;3(2):162-5 [4951728.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1972 Apr;114(4):817-21 [5026246.001]
  • [Cites] Pathol Int. 1999 Jul;49(7):658-62 [10504529.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):802-3 [1514518.001]
  • [Cites] Jpn Circ J. 2000 May;64(5):385-8 [10834456.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):167-72 [10395286.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Arch Pathol Lab Med. 1995 Mar;119(3):266-7 [7887781.001]
  • [Cites] Chest. 1980 Apr;77(4):559-61 [7357984.001]
  • [Cites] Tex Heart Inst J. 1994;21(2):170-4 [8061543.001]
  • [Cites] Chest. 1999 Dec;116(6 Suppl):455S-460S [10619507.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2896-900 [11973650.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):875-7 [10810369.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1926-7 [10892948.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):81-5 [11243902.001]
  • [Cites] Am Heart J. 1987 Mar;113(3):785-90 [3548297.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1616-22 [9603146.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Sep;112(3):637-43 [8800150.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):77-81 [11836672.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):121-9 [11936818.001]
  • [Cites] Chirurg. 2000 Aug;71(8):877-86 [11013806.001]
  • (PMID = 12194802.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


14. Morán-Mendoza A, Alvarado-Luna G, Calderillo-Ruiz G, Serrano-Olvera A, López-Graniel CM, Gallardo-Rincón D: Elevated CA125 level associated with Meigs' syndrome: case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:315-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meigs' syndrome is the association of ovarian fibroma, pleural effusion, and ascites.
  • The patient was a 46-year-old woman with right pleural effusion, ascites, ovarian tumor, and CA125 level of 1808 U/mL.
  • Tomography revealed ascites and bilobate pelvic tumor of approximately 25 cm.
  • The diagnosis of advanced epithelial ovarian cancer was considered, and the patient was treated with chemotherapy.
  • Three chemotherapy schemes were applied due to the total lack of response in tumor volume; however, CA125 decreased to 90 U/mL.
  • Thus, surgery was performed with resection of 25 cm of the left ovarian tumor, with intact capsule and without implants; the result of histopathologic analysis was fibroma.
  • Although the association between ovarian tumor, pleural effusion, ascites, and marked elevation of CA125 is highly indicative of epithelial ovarian cancer, Meigs' syndrome must be considered in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Meigs Syndrome / therapy

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515612.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  • [Number-of-references] 27
  •  go-up   go-down


15. Sugarbaker PH, Yan H, Grazi RV, Shmookler BM: Early localized peritoneal mesothelioma as an incidental finding at laparoscopy. Report of a case and implications regarding natural history of the disease. Cancer; 2000 Sep 15;89(6):1279-84
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early localized peritoneal mesothelioma as an incidental finding at laparoscopy. Report of a case and implications regarding natural history of the disease.
  • BACKGROUND: Peritoneal mesothelioma is regarded as a fatal disease that presents with progressive ascites in a relatively late stage of its natural history.
  • Nodules noted in the pelvis were biopsied and determined to be mesothelioma.
  • Cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy were used for treatment.
  • RESULTS: Multiple (approximately 30) tumor nodules up to 2 mm in dimension and limited to the pelvis were observed and resected.
  • No primary tumor focus was evident.
  • These tumor nodules stained positive for Calretinin and negative for carcinoembryonic antigen immunohistochemically.
  • CONCLUSIONS: In this patient, no incidence for transcoelomic dissemination of mesothelioma from a single primary site was observed.
  • Rather, this patient's clinical presentation suggested that mesothelioma may be multifocal in origin within a limited region of the peritoneal cavity.
  • This hypothesis may support a rationale for aggressive local-regional management of selected patients in whom peritoneal mesothelioma is of limited distribution and mass.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Infertility / diagnosis. Laparoscopy. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11002223.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


16. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • It may involve the pleura, less frequently the peritoneum rarely, the pericardium, the tunica vaginalis testis and ovarian epithelium.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • The symptomatology is insidious and poses difficult problems in diagnosis and treatment.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • He was hospitalized for important weight loss, abdominal pain and tiredness being diagnosed after imaging tests with a giant tumor, localized at the abdominal upper level, which seems to originate from the spleen's superior pole.
  • During surgery we discovered a tumor with cystic parts, intense vascularized, which turn to be adherent in the upper side to the lower face of the left midriff cupola, to the spleen superior pole and 1/3 middle level of the great gastric curve.
  • It was performed surgical ablation of the tumor, splenectomy with favorable postoperative evolution, the patient being now under chemotherapy treatment.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Diseases / etiology. Peritoneal Neoplasms / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Splenectomy. Tomography, X-Ray Computed. Treatment Outcome


17. Dienemann H, Trainer C: [Mesothelioma of the pleura and peritoneum. Diagnostic and therapeutic sequelae]. Chirurg; 2000 Aug;71(8):887-93
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mesothelioma of the pleura and peritoneum. Diagnostic and therapeutic sequelae].
  • [Transliterated title] Mesotheliom der Pleura und des Peritoneums. Diagnostische und therapeutische Folgerungen.
  • In patients with pleural or peritoneal mesothelioma, surgery is a technically difficult procedure.
  • Whereas those rare forms of localized pleural mesotheliomy are being detected incidentally and can be cured by complete resection, most patients with diffuse malignant mesothelioma present with an advanced stage of disease.
  • Most of these patients survive less than 12 months irrespective of the treatment modality.
  • For diffuse pleural mesothelioma, some favorable prognostic factors were identified: IMIG (International Mesothelioma Interest Group), stages I and II, epithelial type, age under 50, female gender.
  • For this subset of patients, a median survival time of between 20 and 30 months is reported.
  • Pleurectomy and decortication are recommended as palliative surgical strategies against pleural effusion.
  • In patients with technically inoperable infiltration of the thoracic wall, irradiation is helpful; sometimes partial remission and relief of pain can be achieved by chemotherapy.
  • [MeSH-major] Mesothelioma / surgery. Peritoneal Neoplasms / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11013807.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 21
  •  go-up   go-down


18. Kuroda K, Ishizawa S, Kudo T, Uotani H, Hosokawa A, Tanaka T, Kitano H, Hori T, Tsukada K, Sugiyama T, Fukuoka J: Localized malignant mesenteric mesothelioma causing small bowel obstruction. Pathol Int; 2008 Apr;58(4):239-43
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized malignant mesenteric mesothelioma causing small bowel obstruction.
  • Malignant mesothelioma is an uncommon lethal neoplasm in the serous membrane in which peritoneal mesothelioma is a rarer form.
  • Herein is reported a case of malignant mesothelioma presenting as a localized mass inside the mesentery causing focal luminal obstruction of the small intestine.
  • The diagnosis of malignant mesothelioma was obtained on repeat double balloon endoscopic biopsy.
  • Partial resection of the small intestine along with the mesentery was performed, followed by a course of chemotherapy.
  • No relapse of the disease has been found in the 8 months' follow up radiologically.
  • To the best of the authors' knowledge this is the first reported case of localized malignant mesothelioma arising inside the mesentery.
  • Mesothelioma should be considered as the differential diagnosis when small bowel obstruction occurs with unknown primary neoplasm.
  • [MeSH-major] Intestinal Obstruction / pathology. Mesentery / pathology. Peritoneal Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Endoscopy, Gastrointestinal. Epithelioid Cells / pathology. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324917.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Hirano H, Takeda S, Sawabata Y, Okumura Y, Maeda H, Hanibuchi M, Ito M, Nakagawa M, Uematsu K: Localized pleural malignant mesothelioma. Pathol Int; 2003 Sep;53(9):616-21
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized pleural malignant mesothelioma.
  • The occurrence of pleural malignant mesothelioma (MM) is unusual and the cases that appear as a localized tumor are extremely rare.
  • A case of localized pleural MM including immunohistochemical findings is presented.
  • Computed tomography (CT) showed an extrapleural mass with a smooth surface and a thickened parietal pleura, and results of a biopsy performed under CT scanning yielded MM.
  • The resected tumor, measuring 3.2 x 3.1 cm, was firm, partially encapsulated, and irregularly shaped.
  • Pathological examinations revealed that it consisted of large polygonal cells, partially showing myxoid patterns, which led to a diagnosis of localized pleural MM.
  • Tumor recurrence was seen, and the duration between initial symptoms and death was 29 months.
  • This case suggests that localized pleural MM has a high proliferative potential and aggressive course, and is considered an early stage of diffuse pleural MM.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Paclitaxel / therapeutic use. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14507319.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 24
  •  go-up   go-down


20. Schallier D, Decoster L, Fontaine C, De Grève J: Pemetrexed-induced eyelid edema: incidence and clinical manifestations. Anticancer Res; 2010 Dec;30(12):5185-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pemetrexed-induced eyelid edema is a rare side-effect of pemetrexed treatment.
  • RESULTS: Eighty-six patients received pemetrexed-containing chemotherapy either as a single agent (45 patients) or in combination with cis- or carboplatin (41 patients).
  • Two patients (2.3%) with stage IV non-small cell lung cancer (NSCLC) presented the edema typically localized in the lower eyelid after first-line treatment with carboplatin-pemetrexed.
  • The edema remained identical in both patients during treatment and regressed in one patient in whom treatment was withdrawn.
  • The physiopathological mechanism and, as a consequence, the treatment and/or prevention of this apparently benign side-effect remains unknown.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Eyelids / drug effects. Female. Humans. Lung Neoplasms / drug therapy. Male. Mesothelioma / drug therapy. Middle Aged. Pemetrexed. Retrospective Studies

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187510.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


21. Attanoos RL, Gibbs AR: The pathology associated with therapeutic procedures in malignant mesothelioma. Histopathology; 2004 Oct;45(4):393-7
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology associated with therapeutic procedures in malignant mesothelioma.
  • AIMS: To describe iatrogenic pathological lesions in malignant pleural mesothelioma.
  • METHODS AND RESULTS: All cases of malignant pleural mesothelioma confirmed by antemortem pleural biopsy and undergoing post mortem examination over a 7-year period (1995-2001) formed the study group.
  • This comprised 48 malignant pleural mesotheliomas [epithelioid (n = 21), biphasic (n = 14) and sarcomatoid (n = 13)].
  • Twenty-eight of 48 (58%) had received chemical (talc) pleurodesis, 30/48 (63%) palliative localized radiotherapy, 6/48 (13%) chemotherapy, and 14/48 (30%) surgery [12/48 (26%) pleural decortication and 2/48 (4%) pleuropneumonectomy].
  • In more chronic cases, paucicellular fibrosis with a foreign body giant cell reaction is noted.
  • The talc is polarizable and deposited in linear fashion within the tumour.
  • Tumour nodules developing subjacent to iatrogenic wound sites were noted in 8/48 (17%) cases.
  • In 6/8 (75%) of these cases, comparative assessment of the locally irradiated subcutaneous chest wall tumour, with background pleural mesothelioma, showed no morphological difference in architectural tumour growth pattern, extent of necrosis, cytological or nuclear pleomorphism, mitotic activity or tumour immunophenotype.
  • In 2/8 (25%) cases the locally irradiated tumour showed prominent bizarre multinucleated tumour giant cells and intense mixed inflammation, a feature not seen in the background (non-irradiated) tumour.
  • All six malignant pleural mesotheliomas receiving chemotherapy appeared refractory to treatment in that chemotherapy did not appear to have any significant effect on the tumour morphology, cytonuclear pleomorphism, mitotic activity, extent of necrosis or immunophenotype.
  • In the 12 decortication specimens and two pleuropneumonectomy resections, post mortem examination identified evidence of residual malignant mesothelioma of similar morphological subtype and immunophenotype to the resected tumour.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pleurodesis. Radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Iatrogenic Disease. Talc / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15469478.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down


22. Gupta NP, Kumar R: Malignant gonadal mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):363-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gonadal mesothelioma.
  • Malignant mesothelioma of the gonads is a rare and highly lethal disease.
  • Most of these tumors arise from the tunica vaginalis, which is a continuation of the mesothelium similar to the pleura and the peritoneum.
  • However, intratesticular and ovarian mesotheliomas have also been described.
  • Occasionally, patients with localized disease at the time of detection have been known to survive for more than 10 years; however, the majority will not live beyond 5 years, with median survival being approximately 23 months.
  • The principle reasons for this are difficulty in making a preoperative diagnosis and advanced stage at the time of treatment.
  • Surgery forms the mainstay of management for all stages of the tumor.
  • Adjuvant therapy in the form of chemotherapy, immunotherapy, or radiotherapy has negligible benefit.
  • For the management of localized disease, we suggest the following protocol: initial staging of suspected cases with computed tomographic scan of the abdomen and pelvis; radical inguinal orchiectomy or hemiscrotectomy; retroperitoneal lymph node dissection in cases with positive nodes on scan or biopsy; and inguinal node dissection in cases requiring hemiscrotectomy.
  • For advanced or recurrent disease, we suggest local radical resection with chemotherapy, including high-dose cisplatin and doxorubicin for two cycles of 5 days each; add local radiotherapy for uncontrolled locally advanced disease.
  • [MeSH-major] Genital Neoplasms, Male / drug therapy. Genital Neoplasms, Male / surgery. Mesothelioma / drug therapy. Mesothelioma / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Dec;144(6):1475-8 [2146405.001]
  • [Cites] Minerva Urol Nefrol. 2000 Mar;52(1):33-5 [11517828.001]
  • [Cites] Surg Today. 1999;29(10):1106-10 [10554340.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):294-306 [11202546.001]
  • [Cites] Br J Radiol. 1999 May;72(857):502-4 [10505018.001]
  • [Cites] Zentralbl Chir. 2001 Mar;126(3):229-32 [11301890.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Br J Urol. 1995 May;75(5):679-80 [7613813.001]
  • [Cites] Histopathology. 2000 Aug;37(2):150-9 [10931239.001]
  • [Cites] Jpn J Clin Oncol. 1991 Oct;21(5):377-83 [1753419.001]
  • [Cites] J Surg Oncol. 1999 Apr;70(4):251-4 [10219022.001]
  • [Cites] Ann Intern Med. 1984 Jan;100(1):19-24 [6197916.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):815-25 [7793480.001]
  • [Cites] Urol Int. 1995;55(4):215-7 [8588269.001]
  • (PMID = 12194801.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


23. Watanabe S, Shimokawa S, Sakasegawa K, Nakamura Y, Sakata R: [Surgical treatment for malignant pleural mesothelioma in eight cases]. Kyobu Geka; 2000 Dec;53(13):1101-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for malignant pleural mesothelioma in eight cases].
  • Between 1987 and March 2000, we have operated on eight patients for malignant mesothelioma which consisted of four of localized type and four of diffuse type.
  • We have aggressively resected mesothelioma combined with chemotherapy whether the tumor was primary or recurrent, and concluded the following.
  • 1) In localized malignant mesothelioma, en-bloc primary tumor resection was possible and additional resection for recurrence was effective and useful for long time survival.
  • 2) In diffuse malignant mesothelioma, complete tumor resection was impossible to even perform pleuropneumonectomy accompanied with partial resection of pericardium and diaphragm and, therefore, the prognosis was poor in four patients and all died around one year.
  • 3) Because recurrent pattern for localized type was diffuse type, diagnosis and surgical treatment in early stage was essential for long time survival.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diaphragm / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Pericardium / surgery. Pleura / surgery. Pneumonectomy. Prognosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127555.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Saynak M, Bayir-Angin G, Kocak Z, Oz-Puyan F, Hayar M, Cosar-Alas R, Karamustafaoglu A, Yurut-Caloglu V, Caloglu M, Yoruk Y: Recurrent solitary fibrous tumor of the pleura: significant response to radiotherapy. Med Oncol; 2010 Mar;27(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent solitary fibrous tumor of the pleura: significant response to radiotherapy.
  • Solitary fibrous tumor (SFT) of the pleura is an uncommon neoplasm with non-specific symptoms and non-pathognomonical radiological findings.
  • Surgery allows establishment of a definitive diagnosis as well as a cure of the disease.
  • The role of radiotherapy or chemotherapy in the management of the disease is unclear because of the rarity of the disease and the successful results of the surgical treatment.
  • Long-term clinical follow-up may be useful for the patients with SFT because of the potential adverse biological behavior of this tumor, which may lead to repeated recurrences and/or malignant transformation.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Solitary Fibrous Tumor, Pleural / radiotherapy
  • [MeSH-minor] Aged. Dyspnea / etiology. Female. Humans. Immunohistochemistry. Palliative Care. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] J BUON. 2008 Jan-Mar;13(1):117-21 [18404798.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Dtsch Med Wochenschr. 2001 Jan 5;126(1-2):12-5 [11200659.001]
  • [Cites] Pathol Int. 2007 Apr;57(4):213-8 [17316417.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):303-7 [15620963.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • (PMID = 19165637.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Tran N, Krueger T, Pan Y, Yan H, Cheng C, Altermatt HJ, Ballini JP, Borle F, Ris HB, Andrejevic-Blant S: Correlation of photodynamic activity and fluorescence signaling for free and pegylated mTHPC in mesothelioma xenografts. Lasers Surg Med; 2007 Mar;39(3):237-44
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of photodynamic activity and fluorescence signaling for free and pegylated mTHPC in mesothelioma xenografts.
  • BACKGROUND/OBJECTIVES: Correlation of photodynamic activity (PDT) and fluorescence signaling for free and pegylated meta-tetrahydroxyphenylchlorin (mTHPC) in nude mice with mesothelioma xenografts.
  • STUDY DESIGN/MATERIALS AND METHODS: Twelve animals received light delivery (20 J/cm(2), 150 mW/cm(2), spot size 1.2 cm) on the tumor and the hind leg 3 days after sensitization with 0.15 mg/kg free mTHPC (n = 6) or equimolar-dosed pegylated mTHPC (n = 6).
  • RESULTS: Pegylated mTHPC resulted in a similar extent of PDT-related tumor necrosis but in lower skin phototoxicity than free mTHPC.
  • Both mTHPC formulations were heterogeneously distributed in the tumor and were mainly localized in perivascular areas.
  • Pegylated mTHPC revealed a higher tumor to skin fluorescence intensity ratio than free mTHPC (P<0.001).
  • CONCLUSIONS: Fluorescence signaling measurement has the potential to predict the photodynamic activity for both mTHPC formulations in mesothelioma xenografts.
  • [MeSH-major] Mesoporphyrins / pharmacology. Mesothelioma / drug therapy. Photochemotherapy. Photosensitizing Agents / pharmacology. Pleural Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc
  • (PMID = 17345623.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


26. Prunotto M, Bosco M, Daniele L, Macri' L, Bonello L, Schirosi L, Rossi G, Filosso P, Mussa B, Sapino A: Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer; 2009 May;64(2):244-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
  • We examined the in vitro effects of imatinib (Novartis Pharma AG, Basel, Switzerland) as a possible inhibitor of PDGFR pathway on cells derived from a recurrence of a pleural malignant solitary fibrous tumor (SFT).
  • SFT-derived cells were treated with imatinib at different time points.
  • Western blotting for PDGFR-beta, phospho-PDGFR-beta or smooth muscle actin (SMA) was performed before and after 96 h of treatment with imatinib.
  • Western blotting showed that PDGFR-beta was highly expressed and phosphorylated in SFT-derived cells and imatinib treatment reduced PDGFR-beta phosphorylation and SMA expression.
  • With the limit of experimental findings, our results support a possible future application of imatinib as a candidate molecule in the target therapy of malignant SFTs over-expressing wild-type PDGFR.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Piperazines / pharmacology. Pyrimidines / pharmacology. Receptor, Platelet-Derived Growth Factor beta / drug effects. Solitary Fibrous Tumor, Pleural / metabolism
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Blotting, Western. Cells, Cultured. Cisplatin / administration & dosage. Female. Fluorescent Antibody Technique. Fluorouracil / administration & dosage. Humans. Imatinib Mesylate. In Vitro Techniques. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Pneumonectomy. Radiotherapy. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041155.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement